arrow
W

William S. Stone

Beth Israel Deaconess Medical Center
H指数:56
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association Between Social and Role Functioning and Transition to Psychosis in the North American Prodrome Longitudinal Study Consortium

社会与角色功能与精神病发作之间的关系:北美前驱期纵向研究联盟的研究

2026-08-110
OAAI
Processing Speed and Verbal Learning Ability as Predictors of Assessor-Rated and Ecological Momentary Assessment Self-Reported Functioning: Findings from AMP SCZ

处理速度和言语学习能力作为评估者评定和生态瞬时评估自报功能表现的预测因素:AMP SCZ的研究发现

2026-08-030
PRE
Correlation networks of blood proteins in the neuroimmunology of schizophrenia—replication and extension

精神分裂症神经免疫学中血液蛋白质的相关网络——重复与扩展

2026-04-110
OAAI
Machine learning enables efficient neurocognitive profiling in patients with schizophrenia

机器学习赋能精神分裂症患者高效神经认知特征分析

2026-01-010
PRE
Neighborhood Characteristics and Social Functioning: Exploring Shared and Distinct Psychosocial Pathways Among Individuals at Clinical High-Risk for Psychosis

邻里特征与社会功能:探索精神分裂症临床高风险个体中共享和独特的心理社会途径

2025-11-010
PRE
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
Shift in sex and age of individuals at a clinical high risk (CHR) for psychosis: relation to differences in recruitment methods and effect on sample characteristics

精神病临床高风险(CHR)个体在性别和年龄上的变化:与招募方法差异的关系及其对样本特征的影响

2025-10-060
OAAI
Predictors and Moderators of Long-Term Outcome of Persons at Clinical High Risk for Psychosis: Methods and Preliminary Data

精神分裂症临床高风险人群长期结局的预测因子和调节因子:方法与初步数据

2025-08-010
OAAI
The moderating role of lifetime social engagement on the relationship between C-reactive protein and negative symptoms among young adults at clinical high risk for psychosis

终身社会参与在C反应蛋白与精神病临床高风险青年人群负性症状关系中的调节作用

2025-07-270
PRE
Cognitive subtypes in youth at clinical high risk for psychosis

精神分裂症临床高风险青少年的认知亚型

2025-07-020
PRE
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Cultural variables influence performance on the MATRICS Consensus Cognitive Battery among people at clinical high risk for psychosis

文化变量影响临床高风险精神病患者在MATRICS共识认知电池中的表现

2025-06-010
PRE
Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons

在精神病和健康比较的临床高风险中,与青少年的不匹配负相关性受损有关的邻里社会分裂

2025-04-010
PRE
Emergence and Dynamics of Delusions and Hallucinations Across Stages in Early Psychosis

早期精神分裂症各阶段妄想和幻觉的出现与发展动态

2025-02-260
OA
Unique Functional Neuroimaging Signatures of Genetic Versus Clinical High Risk for Psychosis
2025-01-010
OAAI